Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex

Jun Fan, Emory University
Changliang Shan, Emory University
HeeBum Kang, Emory University
Shannon Elf, Emory University
Jianxin Xie, Cell Signaling Technology, Inc.
Meghan Tucker, Cell Signaling Technology, Inc.
Ting-Lei Gu, Cell Signaling Technology, Inc.
Mike Aguiar, Cell Signaling Technology, Inc.
Scott Lonning, Cell Signaling Technology, Inc.
Huaibin Chen, New York University

Only first 10 authors above; see publication for full author list.

Journal Title: Molecular Cell
Volume: Volume 53, Number 4
Publisher: Elsevier (Cell Press) | 2014-02-20, Pages 534-548
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.molcel.2013.12.026
Permanent URL: https://pid.emory.edu/ark:/25593/pg485

Final published version: http://dx.doi.org/10.1016/j.molcel.2013.12.026
Accessed October 20, 2017 12:35 AM EDT
Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex

Jun Fan,1,8 Changliang Shan,1,8 Hee-Bum Kang,1,8 Shannon Elf,1 Jianxin Xie,2 Meghan Tucker,3 Ting-Lei Gu,3 Mike Aguiar,3 Scott Lonning,3 Huabin Chen,4 Moosa Mohammadi,8 Laura-Mae P. Britton,5 Benjamin A. Garcia,5 Masa Aleckovic,6 Yiben Kang,2 Stefan Kaluz,2 Narra Devi,2 Erwin G. Van Meir,1,2 Taro Hitosugi,1,9 Jae Ho Seo,1 Sagar Lonial,1 Manila Gaddh,1 Martha Arellano,1 Hanna J. Khoury,1 Fadlo R. Khuri,1 Titus J. Boggon,7 Sumin Kang,1 and Jing Chen1,*

1Department of Hematology and Medical Oncology
2Department of Neurosurgery
Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322, USA
3Cell Signaling Technology, Inc. (CST), Danvers, MA 01923, USA
4Department of Biochemistry & Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA
5Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104, USA
6Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
7Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
8These authors contributed equally to this work
9Present address: Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
*Correspondence: jchen@emory.edu
http://dx.doi.org/10.1016/j.molcel.2013.12.026

SUMMARY

Mitochondrial pyruvate dehydrogenase complex (PDC) is crucial for glucose homeostasis in mammalian cells. The current understanding of PDC regulation involves inhibitory serine phosphorylation of pyruvate dehydrogenase (PDH) by PDH kinase (PDK), whereas dephosphorylation of PDH by PDH phosphatase (PDP) activates PDC. Here, we report that lysine acetylation of PDHA1 and PDP1 is common in epidermal growth factor (EGF)-stimulated cells and diverse human cancer cells. K321 acetylation inhibits PDHA1 by recruiting PDK1, and K202 acetylation inhibits PDP1 by dissociating its substrate PDHA1, both of which are important in promoting glycolysis in cancer cells and consequent tumor growth. Moreover, we identified mitochondrial ACAT1 and SIRT3 as the upstream acetyltransferase and deacetylase, respectively, of PDHA1 and PDP1, while knockdown of ACAT1 attenuates tumor growth. Furthermore, Y381 phosphorylation of PDP1 dissociates SIRT3 and recruits ACAT1 to PDC. Together, hierarchical, distinct posttranslational modifications act in concert to control molecular composition of PDC and contribute to the Warburg effect.

INTRODUCTION

Mammalian cells use glucose to generate energy. Normal cells produce ATP in the mitochondria through oxidative phosphorylation (OXPHOS), whereas under hypoxia, glucose is converted to lactate through glycolysis to produce ATP (Cairns et al., 2011; Kroemer and Pouyssegur, 2008). Glucose oxidation starts from the irreversible decarboxylation of glycolytic intermediate pyruvate to acetyl coenzyme A (acetyl-CoA) in mitochondria by pyruvate dehydrogenase complex (PDC), a large complex of three functional enzymes: E1, E2, and E3. PDC is organized around a 60-meric dodecahedral core formed by dihydrolipoyl transacetylase (E2) and E3-binding protein (E3BP) (Hiromasa et al., 2004), which binds pyruvate dehydrogenase (PDH; E1), dihydrolipoamide dehydrogenase (E3), pyruvate dehydrogenase kinase (PDK), and pyruvate dehydrogenase phosphatase (PDP) (Read, 2001). PDH is the first and most important enzyme component of PDC that converts pyruvate to acetyl-CoA, which, along with the acetyl-CoA from the fatty acid β-oxidation, enters the Krebs cycle to produce ATP and electron donors, including NADH. Thus, PDC links glycolysis to the Krebs cycle and plays a central role in glucose homeostasis in mammals (Harris et al., 2002).

Since PDH catalyzes the rate-limiting step during the pyruvate decarboxylation, activity of PDH determines the rate of PDC flux. The current understanding of PDC regulation involves the cyclic phosphorylation and dephosphorylation of PDH catalyzed by specific PDKs and PDPs, respectively (Holness and Sugden, 2003). PDK1 is a Ser/Thr kinase that inactivates PDC by phosphorylating at least one of three specific serine residues of PDHA1 (sites 1, 2, and 3 are S293, S300, and S232, respectively), while dephosphorylation of PDHA1 by PDP1 restores PDHA1 and, subsequently, PDC activity (Roche et al., 2001). The Warburg effect describes the observation that cancer cells take up more glucose than normal tissue and favor aerobic glycolysis more than mitochondrial oxidation of pyruvate (Kroemer and Pouyssegur, 2008; Vander Heiden et al., 2009;
An emerging concept suggests that the metabolic change in cancer cells to rely more on glycolysis may be due in part to attenuated mitochondrial function through inhibition of PDC. In consonance with this concept, gene expression of PDK1, in addition to diverse glycolytic enzymes, is upregulated by Myc and hypoxia-inducible factor-1α (HIF-1α) in cancer cells (Kim et al., 2006a, 2007; Papandreou et al., 2006). Moreover, we also reported recently that diverse oncogenic tyrosine kinases (TKs), including FGFR1, are localized to different mitochondrial compartments in cancer cells, where they phosphorylate and activate PDK1 to inhibit PDH (and consequently PDC), providing a metabolic advantage to tumor growth (Hitosugi et al., 2011).

Here, we report a mechanism where lysine acetylation of PDHA1 and PDP1 contributes to inhibitory regulation of PDC, providing complementary insight into the current understanding of PDHA1 regulation through the phosphorylation/dephosphorylation cycle.

**RESULTS**

**K321 and K202 Acetylation Inhibits PDHA1 and PDP1, Respectively**

Our recent finding that tyrosine phosphorylation activates PDK1 (Hitosugi et al., 2011) suggests an important role for posttranslational modifications in PDC regulation. To examine the potential effect of lysine acetylation on PDC activity, we treated lung cancer H1299 cells that overexpress fibroblast growth factor receptor 1 (FGFR1) (Marek et al., 2009) with deacetylase inhibitors nicotinamide (NAM) and trichostatin A (TSA) for 16 hr, which led to increased global lysine acetylation in cells without affecting cell viability (Figure S1A available online). NAM and TSA (NAM+TSA) treatment resulted in decreased PDC flux rate in isolated mitochondria from H1299 cells (Figure 1A), suggesting that alteration of global lysine acetylation levels leads to PDC inhibition in human cancer cells. Interestingly, multiple proteomics-based studies performed by our collaborators at Cell Signaling Technology (CST) identified key components of PDC, including PDHA1 (http://www.phosphosite.org/proteinAction.do?id=1271&showAllSites=true) and PDP1 (http://www.phosphosite.org/proteinAction.do?id=19516&showAllSites=true), but not PDK1 (http://www.phosphosite.org/proteinAction.do?id=2352&showAllSites=true), as acetylated at a group of lysine residues in human cancer cells. To test the hypothesis that lysine acetylation might directly affect PDHA1 and PDP1 activity, we incubated recombinant FLAG-tagged PDHA1 and PDP1 with cell lysates from NAM+TSA-treated H1299 cells. Such treatment results in increased lysine acetylation of PDHA1 (Figure 1B, bottom) and PDP1 (Figure 1C, right), accompanied by reduced PDHA1 enzyme activity (Figure 1B, top) and PDP1 phosphatase activity, as assessed by the ability of PDP1 to dephosphorylate S293 of substrate PDHA1 (Figure 1C, left), respectively. These results suggest that lysine acetylation inhibits PDHA1 and PDP1 and, consequently, PDC flux.

To identify the lysine sites that mediate acetylation-dependent inhibition of PDHA1 and PDP1 upon treatment with NAM+TSA, we performed mass spectrometry-based experiments to examine glutathione S-transferase (GST)-PDHA1 and GST-PDP1 proteins incubated with NAM+TSA-treated H1299 cell lysates. We identified K18 of PDHA1 and K104, K357, K468, and K502 of PDP1 as acetylated (Figure S1B), in addition to K39, K244, and K321 of PDHA1 and K202 of PDP1, which were posted on the CST website (http://www.phosphosite.org/homeAction.do). We next performed mutational analysis and generated diverse acetyl-deficient K→R and acetyl-mimetic K→Q mutants of PDHA1 and PDP1 to replace each of the lysine residues that were identified as acetylated. We found that only substitutions of PDHA1 K321 and PDP1 K202 conferred resistance to the enzymes in terms of NAM+TSA treatment-induced inhibition of PDHA1 enzyme activity (Figure 1D) and PDP1 phosphatase activity (Figure 1E), respectively. We performed an isoelectric focusing (IEF) experiment and estimated the stoichiometry of lysine acetylation of recombinant PDHA1 (~70%) and PDP1 (~50%) upon treatment with cell lysates from H1299 cells treated with NAM+TSA (Figure S1G). This is consistent with our previous observations that treatment with NAM+TSA-treated cell lysates resulted in an ~70% decrease in enzyme activity of recombinant PDHA1 (Figure 1B) and an ~50% decrease in phosphatase activity of recombinant PDP1 (Figure 1C). Note in Figures 1B and 1C that both the acetyl-deficient K321R and acetyl-mimetic K321Q mutants of PDHA1 as well as K202R and K202Q mutants of PDP1 showed resistance to NAM+TSA treatment, where K→R mutants were catalytically more active and K→Q mutants were catalytically less active, suggesting that the enzyme activity change of PDHA1 and PDP1 was most likely due to lysine acetylation.

We next examined whether K321 acetylation-dependent inhibition of PDHA1 is dependent or independent of serine phosphorylation-dependent inhibition of PDHA1. We found that, compared to control GST-PDHA1 WT, acetyl-deficient K321R and acetyl-mimetic K321Q variants of GST-PDHA1 that were transiently transfected in H1299 cells demonstrate decreased and increased S293 phosphorylation, respectively (Figure 1F). These results suggest that K321 acetylation of PDHA1 functions as an upstream event that promotes PDK1-dependent phosphorylation and inhibition of PDHA1. We hypothesized that K321 acetylation may potentiate recruitment of PDK1 to PDHA1 and thus performed a GST pull-down assay. As shown in Figures 1G and 1D, FLAG-PDHA1 WT and control K18R, K29R, or K244R mutants incubated with NAM+TSA-treated H1299 cell lysates show increased binding of PDHA1 protein to GST-specific affinity resin-immobilized purified GST-PDK1. In contrast, substitution at K321 of PDHA1 abolishes the increased PDK1 binding induced by NAM+TSA treatment. We next tested whether K202 acetylation similarly affects PDP1-PDHA1 association. We found that incubation of purified GST-PDP1 WT and control K104R, K357R, K468R, or K502R mutants, but not K202R mutant, with NAM+TSA-treated cell lysates abolishes binding of purified FLAG-PDHA1 to GST-specific affinity resin-immobilized GST-PDP1 protein (Figure 1H). Together, these results suggest that lysine acetylation of PDHA1 and PDP1 regulates the molecular composition of PDC, which facilitates S293 phosphorylation of PDHA1, leading to inhibition of PDHA1 and, subsequently, PDC.
Lysine Acetylation Inhibits PDP1 and PDHA1

(A) Relative PDC activity (% CO₂ production)

(B) Relative PDC activity (%)

(C) Relative PDP1 activity (%)

(D) Relative PDHA1 activity (%)

(E) Relative PDP1 activity (%)

(F) GST-PDHA1

(G) rFLAG-PDHA1

(H) GST-PDP1

(legend on next page)
Lysine Acetylation of PDHA1 and PDP1 Is Induced by EGF Stimulation and Is Common in Diverse Human Cancer Cells, which Is Important to Promote Glycolysis and Tumor Growth

We next generated two specific acetyl-PDHA1 and acetyl-PDP1 antibodies and detected NAM+TSA treatment-dependent acetylation at K321 of PDHA1 and K202 of PDP1 proteins, respectively (Figure S1E). Using these acetyl-specific antibodies, we found that P321 acetylation and S293 phosphorylation of PDHA1, as well as K202 acetylation of PDP1, are increased in EGF-treated human 3T3 and 293T cells (Figures 2A and S1F, respectively). Moreover, acetylation of PDHA1 K321 and PDP1 K202 is common in diverse human tumor cells, including H1299 and A549 lung cancer, Tu212 and 212LN head and neck cancer, and MCF7 and MDA-MB-231 breast cancer cells (Figure 2B, left), as well as a group of leukemia cells associated with distinct leukemogenic tyrosine kinases, including HEL (JAK2 V617F), K562 (BCR-ABL), KG1a (FOP2-FGFR1), and Mo91 (TEL-TrkC) cells (Figure 2B, middle). Furthermore, we observed that acetylation levels of PDHA1 K321 and PDP1 K202 are increased in primary leukemia cells from four acute myeloid leukemia (AML) patients compared to peripheral blood cells from a representative healthy donor (Figure 2B, right).

Since EGF stimulation induces glycolysis and promotes cell proliferation, whereas most cancer cells are highly proliferative and glycolytic (Kroemer and Pouyssegur, 2008; Sumi et al., 1984), we next tested whether K321 and K202 acetylation-dependent inhibition of PDHA1 and PDP1, respectively, is important for glycolysis and cancer cell proliferation. We generated “rescue” H1299 cells with stable knockdown of endogenous PDHA1 or PDP1, followed by rescue expression of shRNA-resistant FLAG-PDHA1 WT and K321R or PDP1 WT and K202R, which harbor silent mutations in the target regions of shRNA (Figure S1G). As shown in Figures 2C and S1H, knockdown or rescue expression of PDHA1 WT and PDP1 WT does not affect H1299 cell proliferation under normoxic or hypoxic conditions. In contrast, rescue expression of catalytically active, acetyl-deficient PDHA1 K321R or PDP1 K202R significantly attenuates cell proliferation under hypoxia, but not normoxia. Note that lysine acetylation levels of PDP1 and PDHA1 in cells were comparable under normoxia and hypoxia (Figure S1I). In consonance with these findings, compared to corresponding PDHA1 and PDP1 WT cells, PDHA1 K321R and PDP1 K202R cells demonstrate increased PDC flux rate (Figure 2D), decreased glycolytic rate (Figure S1J), and lactate production (Figure 2E) under both normoxic and hypoxic conditions, as well as increased oxygen consumption rate (Figure 2F) with elevated intracellular ATP (Figure 2G) and reactive oxygen species (ROS) (Figure S1K) levels under normoxia. In addition, compared to corresponding control WT cells, PDHA1 K321R and PDP1 K202R cells are more sensitive to treatment with ATP synthase inhibitor oligomycin in terms of inhibition of oxygen consumption, ATP production, and cell proliferation (Figures 2F–2H, respectively). Consistent with these findings, compared to corresponding control WT cells, PDHA1 K321R and PDP1 K202R cells are more sensitive to hypoxia in terms of inhibition of ATP production (Figure 2I).

These data together suggest that abolishment of lysine acetylation of PDHA1 and PDP1 results in a metabolic change to allow cells to rely more on OXPHOS, providing a metabolic disadvantage to cell proliferation under hypoxia.

We next performed xenograft experiments and found that the growth rate (Figure S2A) and masses of tumors (Figure 2J) derived from PDHA1 K321R rescue H1299 cells, compared to those of tumors formed by the control PDHA1 WT rescue cells, were significantly reduced, with decreased K321 acetylation and decreased expression of proliferation marker Ki67 (Figure S2B, left and right, respectively) as well as increased PDC flux, decreased lactate production, and increased oxygen consumption rate (Figure S2C) in tumor cells. Similar results were obtained in xenograft mice using PDP1 WT and K202R cells (Figures 2K and S2C–S2F). Together, these data demonstrate an important role for lysine acetylation of PDHA1 and PDP1 in tumor growth.

Mitochondrial ACAT1 Is the Upstream Acetyltransferase of PDHA1 and PDP1

To identify the upstream acetyltransferase(s) of PDHA1 and PDP1, we constructed a “targeted” lentiviral shRNA library that targets 50 out of 71 known acetyltransferases in the human genome, which are available in the shRNA library targeting the whole human genome (Open Biosystems) (Figure 3A). Using this library, we performed PDP1 phosphatase assay-based screening studies using recombinant PDP1 incubated with cell lysates from H1299 cells with knockdown of particular acetyltransferases by lentiviral transduction in the presence or absence of NAM+TSA (Figure 3A). We found that lentiviral shRNA-mediated knockdown of acetyl-CoA acetyltransferase 1 (ACAT1) results in increased PDP1 activity with decreased...
Figure 2. Lysine Acetylation of PDHA1 and PDP1 Is Important to Promote Glycolysis as well as Consequent Cancer Cell Proliferation under Hypoxia and Tumor Growth

(A) Immunoblotting of lysates of 3T3 cells treated with EGF stimulation for different times as indicated using specific acetyl- or phospho-PDHA1 and acetyl-PDP1 antibodies.

(B) Immunoblotting to detect acetylation levels of PDHA1 K321 and PDP1 K202 in diverse human tumor (left) and leukemia (middle) cells as well as human primary leukemia cells isolated from peripheral blood (PB) samples from representative AML patients (right). Normal proliferating human foreskin fibroblasts (HFF), HaCaT keratinocyte cells, and PB cells from a healthy human donor were included as controls.

(legend continued on next page)
Lysine acetylation that is resistant to NAM+TSA treatment, whereas knockdown of other acetyltransferases (TAFII31 and AA-NAT as representatives) does not affect NAM+TSA-induced lysine acetylation and inhibition of PDP1 (Figure 3B). Similarly, treatment with cell lysates from H1299 cells with knockdown of PDHA1 results in decreased lysine acetylation and increased enzyme activity of PDHA1 that is resistant to NAM+TSA treatment (Figure 3C). We next confirmed that ACAT1 directly acetylates PDHA1 and PDP1 in an in vitro lysine acetylation assay using purified recombinant ACAT1 incubated with purified GST-tagged PDHA1 and PDP1, where acetylated PDHA1 and PDP1 were detected by pan acetyl-Lys and specific acetyl-PDHA1/PDP1 antibodies (Figures S3A and S3D, respectively).

Moreover, incubation with ACAT1 significantly inhibits enzyme activity of PDHA1 WT and control K244R mutant, but not K321R mutant (Figure 3E). In consonance with our findings in Figure 1G, compared to PDHA1 WT control, which is resistant to ACAT1 treatment, ACAT1 incubation promotes PDK binding to PDHA1, whereas K321R mutant has decreased ability to bind PDK1 (Figure 3F). In addition, ACAT1 treatment significantly inhibits phosphatase activity of PDP1 WT and control K357R mutant, but not K202R mutant (Figure 3G). Consistent with results shown in Figure 1H, ACAT1 treatment abolishes the ability of PDP1 WT, but not K202R mutant, to bind PDHA1 (Figure 3H). Thus, these results together demonstrate ACAT1 as the upstream acetyltransferase of PDHA1 and PDP1.

**ACAT1 Is Important for Cancer Cell Proliferation and Tumor Growth, which Signals through the PDP-PDHA1 Axis to Promote Glycolysis**

We reasoned that if ACAT1 is responsible for lysine acetylation and, subsequently, inhibition of PDHA1 and PDP1, ACAT1 is important for the metabolic alteration in cancer cells to rely more on glycolysis. Indeed, we found that stable knockdown of ACAT1 in H1299 cells results in increased PDC flux rate with decreased acetylation levels of PDHA1 K321 and PDP1 K202 (Figure 4A). In addition, compared to control cells harboring an empty vector and similar to PDHA1 K321R and PDP1 K202R cells described in Figures 2 and S1, ACAT1 knockdown cells show a decreased cell proliferation rate under hypoxia, but not normoxia (Figure 4B), with decreased glycolytic rate (Figure S3B) and lactate production (Figure 4C). These cells also show increased oxygen consumption rate (Figure 4D) with elevated intracellular ATP (Figure S3C) and ROS (Figure S3D) levels. Moreover, compared to control vector cells, ACAT1 cells are more sensitive to treatment with ATP synthase inhibitor oligomycin in terms of inhibition of oxygen consumption, ATP production, and cell proliferation (Figures 4D, S3C and S3E, respectively). Consistent with these findings, we found that compared to control WT rescue cells, expression of PDP1 K202R or PDHA1 K321R, or stable knockdown of ACAT1, did not induce apoptosis (Figure S3F). In contrast, H1299 cells expressing K→R mutants, or with ACAT1 knockdown, demonstrated a decreased cell proliferation index (PI) with an increased percentage of cells at G0/G1 phase but decreased cell percentages at S and G2/M phases (Figure S3G).

Furthermore, in a xenograft experiment, the growth rate (Figure S3F) and masses (Figures 4E and S3G, left) of tumors derived from ACAT1 knockdown cells, compared to those of tumors formed by control cells, were significantly reduced, likely due to decreased cell proliferation assessed by decreased immunohistochemistry (IHC) staining of proliferation marker Ki67 (Figure S3G, right). In addition, acetylation levels of PDHA1 K321 and PDP1 K202 are markedly reduced in tumors derived from ACAT1 knockdown cells compared to those formed by control vector cells (Figure 4F). Consistent with these findings, we found increased IHC staining of HIF-1α and its target GLUT1 (Figure S3J) and increased mRNA levels of a group of markers of hypoxia, including VEGF, GLUT1, CA9, and BHLHB2, that are transcription targets of HIF-1α (Figure S3K), in tumors from mice injected with ACAT1 knockdown cells compared to tumors derived from control vector cells. Similar results were obtained using samples of tumors derived from PDHA1 K321R or PDP1 K202R rescue cells compared to tumors derived from corresponding control cells. These data together suggest that tumors derived from ACAT1 knockdown (KD) cells, or PDHA1 K321R or PDP1 K202R rescue cells, are more hypoxic than tumors derived from corresponding control cells.

We acknowledge that PDHA1 and PDP1 might not be the only substrates of ACAT1. To determine whether the effect of ACAT1 knockdown on cancer cell metabolism and cell proliferation is predominantly mediated through activation of the PDP-PDHA1 axis and, subsequently, PDC, we next examined the effect of expressing distinct acetyl-mimetic K→Q and acetyl-deficient K→R mutants of PDHA1 and PDP1 on ACAT1 knockdown cells (Figures S4A and S4B). We found that, compared to control vector cells, expression of catalytically less active PDP1 K202Q mutant in ACAT1 knockdown cells reverses the ACAT1 deficiency and results in increased PDC flux rate (Figure 4G), decreased lactate production (Figure 4H), and increased oxygen consumption (Figure 4I). Moreover, expression of PDP1 K202Q not only completely rescued the reduced cell proliferation rate of ACAT1 knockdown cells under hypoxia, but also conferred a cell proliferation rate to ACAT1 knockdown cells that exceeds that of control vector cells (Figure 4J). In contrast, H1299 cells with expression of FLAG-PDP1 WT or catalytically more active...
PDP1 K202R show phenotypes similar to ACAT1 knockdown cells, and PDP1 WT or K202R expression in ACAT1 knockdown cells cannot rescue the aforementioned phenotypes as PDP1 K202Q does (Figures 4G–4J). Similar results were obtained using ACAT1 knockdown cells with expression of PDHA1 K321Q and K321R cells (Figures S4C–S4F). These data together demonstrate that ACAT1 predominantly signals through the PDP1-PDHA1 axis to promote glycolysis and confer a proliferative advantage to cancer cells.

**Mitochondrial SIRT3 Is the Upstream Deacetylase of PDHA1 and PDP1**

We also sought to identify the mitochondrial deacetylase that acts in concert with ACAT1. We tested NAD⁺-dependent deacetylase SIRT3, which was reported to regulate global lysine acetylation in mitochondria (Lombard et al., 2007). Compared to control vector cells, H1299 cells with stable knockdown of SIRT3 (Figure S5A), but not the control mitochondrial deacetylase SIRT5 (Figure S5A), show decreased PDC flux rate in isolated mitochondria. In addition, incubation with cell lysates from SIRT3 knockdown cells results in increased lysine acetylation and inhibition of recombinant PDHA1 and PDP1 (Figures 5B and 5E, respectively). Moreover, as shown in Figures 5D and 5E, treatment with recombinant ACAT1 results in increased K321 and K202 acetylation of PDHA1 and PDP1, respectively, which is abolished by sequential treatment with recombinant SIRT3. Conversely, treatment with recombinant SIRT3 results in decreased lysine acetylation of PDHA1 and PDP1 (Figures S5B and S5C, respectively) and, in particular, decreased K321 and K202 acetylation of SIRT3-treated PDHA1 and PDP1, respectively (Figures S5D and S5E, respectively), which is restored by sequential ACAT1 treatment. Moreover, we detected ACAT1 and SIRT3 in mitochondria along with mitochondrial PDHA1 and PDP1 in H1299 cells (Figure 5F). We further localized these proteins within mitochondria biochemically by performing subfractionation of highly purified mitochondria from H1299 cells. As shown in Figure 5G, we found that PDHA1, PDP1, ACAT1, and SIRT3 colocalize in not only the mitochondrial matrix (Ma), but also the mitochondrial outer membrane (Om) and the intermembrane space (IMS), while a fraction of PDP1 and ACAT1, but not PDHA1 and SIRT3, were also detected in the mitochondrial inner membrane (IM). These data together demonstrate that SIRT3 directly deacylates PDHA1 and PDP1 and acts in concert with ACAT1 to regulate PDHA1 and PDP1 by cyclic deacetylation and acetylation in mitochondria.

**Y381 Phosphorylation of PDP1 Recruits ACAT1 and Dissociates SIRT3 to Promote Lysine Acetylation of PDHA1 and PDHA1 and the Warburg Effect**

To better understand how PDHA1 and PDP1 are regulated, we tested whether tyrosine kinase signaling, commonly activated in proliferating cells and cancer cells, regulates lysine acetylation of PDHA1 and PDP1. We found that treatment with FGFR1 inhibitor TKI258 in lung cancer H1299 cells that overexpress FGFR1 (Marek et al., 2009) results in decreased K321 and K202 acetylation of PDHA1 and PDP1, respectively (Figure 6A). Since we observed in a GST pull-down assay that FLAG-ACAT1 and Myc-SIRT3 interact with GST-tagged PDHA1 and PDP1 (Figures S6A and S6B), we next determined whether FGFR1 regulates recruitment of ACAT1 and/or SIRT3 to PDP1. As shown in Figure 6B, treatment with TKI258 results in decreased endogenous ACAT1 but increased endogenous SIRT3 binding to endogenous PDP1 in H1299 cells. Because both PDPA and PDHA1 are part of PDC, which is a huge complex, we next determined which component, PDPA or PDHA1, is important to recruit ACAT1 and SIRT3 to PDC. We found that stable knockdown of PDP1 results in decreased PDHA1-ACAT1 and PDHA1-SIRT3 association (Figures 6C and 6D, left panels, respectively). In contrast, knockdown of PDHA1 does not affect PDPA-ACAT1 and PDPA-SIRT3 association (Figures 6C and 6D, right panels, respectively). These results together suggest that tyrosine kinase signaling regulates PDPA, but not PDHA1, to control accessibility of ACAT1 and SIRT3 to PDC.

Moreover, we found that recombinant FGFR1 directly phosphorylates GST-PDP1 in an in vitro FGFR1 kinase assay, leading to increased FLAG-ACAT1 but decreased Myc-SIRT3 binding to tyrosine-phosphorylated GST-PDP1 in the following GST pull-down assay (Figure 6E). To identify the tyrosine site(s) of PDP1 that mediate phosphorylation-dependent recruitment of ACAT1 and/or dissociation of SIRT3, we performed mass spectrometry-based experiments to examine purified PDP1 protein incubated with recombinant FGFR1. We identified Y79, Y94, and Y381 of PDP1 as phosphorylated (Figure S6C), in addition to Y46 of PDP1 posted on the CST website. We next performed mutational analysis and generated diverse phosphorylation-deficient Y→F mutants of PDP1 to replace each of the identified phosphotyrosine residues. As shown in Figure 6F, we found...
Figure 4. ACAT1 Signals through Inhibition of PDC by Acetylating PDHA1 and PDP1 to Promote Glycolysis and Tumor Growth

(A) H1299 cells with stable knockdown of ACAT1 by shRNA and control cells harboring an empty vector were tested for PDC flux rate (left) and western blot (right).

(B–D) ACAT1 KD cells were tested for cell proliferation rate under normoxia and hypoxia (B), lactate production (C), and oxygen consumption in the presence and absence of ATP synthase inhibitor oligomycin (D).

(E) Tumor masses in xenograft nude mice injected with ACAT1 knockdown cells compared to mice injected with control vector cells are shown. p values were determined by a two-tailed paired Student’s t test.

(F) Western blot results show K321 acetylation levels of PDHA1 (top) and K202 acetylation levels of PDP1 (bottom) in tumor lysates.

(G–J) Stable ACAT1 knockdown cells with stable expression of FLAG-PDP1 WT (left), acetyl-mimetic form K202Q, or acetyl-deficient form K202R of FLAG-PDP1 (right) were tested for PDC flux (G), lactate production (H), oxygen consumption (I), and cell proliferation rate under hypoxia (J). The error bars represent mean values ± SD. See also Figures S3 and S4.
that substitution of PDP1 Y381 with phenylalanine abolishes the inhibition of PDP1 phosphatase activity induced by treatment with SIRT3 knockdown cell lysates. In addition, treatment with FGFR1 results in increased ACAT1 (Figure 6G) but decreased SIRT3 (Figure 6H) binding to PDP1 WT and control Y94F mutant. In contrast, PDP1 Y381F mutant is resistant to FGFR1 treatment, which maintains basal-level binding to ACAT1 (Figure 6G) but binds constitutively to SIRT3 (Figure 6H) in the presence of FGFR1.

In addition, EGF treatment results in increased ACAT1 binding but decreased SIRT3 association to PDP1 in 3T3 cells (Figure 6I). Recombinant EGFR (Figure 6J) and several other tyrosine kinases, including ABL, FLT3, and JAK2 (Figures S6D–S6F, respectively), which are frequently dysregulated in diverse human cancers, also directly phosphorylate PDP1 WT, leading to decreased SIRT3 binding, whereas Y381F mutation abolishes tyrosine phosphorylation-dependent disruption of PDP1-SIRT3 association. We also generated an antibody that specifically recognizes PDP1 phospho-Y381. Using this antibody, we found that active recombinant FGFR1 and EGFR directly phosphorylate purified recombinant PDP1 at Y381 (Figure S6G). In addition, we found that treatment with FGFR1 inhibitor TKI258 resulted in a decreased Y381 phosphorylation level of mitochondrial PDP1 in H1299 cells, where a fraction of FGFR1 was detected in

Figure 5. Mitochondrial SIRT3 Is the Upstream Deacetylase of PDHA1 and PDP1

(A) Control vector and stable SIRT3 knockdown cells were tested for PDC flux (top). SIRT3 protein level was detected by western blot (bottom). (B and C) Purified PDHA1 (B) and PDP1 (C) were incubated with cell lysates from H1299 cells with stable knockdown of SIRT3 or an empty vector, followed by PDHA1 and PDP1 activity assays (top) and western blot (bottom). (D and E) Purified PDHA1 WT and K321R mutant (D) or PDP1 WT and K202R mutant (E) were treated with rACAT1, followed by incubation with recombinant SIRT3 and western blot. (F) Western blot results show colocalization of PDHA1, PDP1, ACAT1, and SIRT3 in mitochondria of H1299 cells. Cytosolic β-actin, mitochondrial TOM40, and nuclear PARP were included as control markers. (G) Western blot results show colocalization of PDHA1, PDP1, ACAT1, and SIRT3 in the outer membrane (Om), intermembrane space (IMS), and matrix (Ma) of mitochondria in H1299 cells. TOM40, cytochrome c (Cyto C), complex I 39 kDa protein, and manganese superoxide dismutase (MnSOD) are markers for Om, IMS, inner membrane (Im), and Ma, respectively. The error bars represent mean values ± SD. See also Figure S5.
Figure 6. Y381 Phosphorylation of PDP1 Recruits ACAT1 but Dissociates SIRT3 to Acetylate PDP1 and PDHA1

(A) Cell lysates from H1299 cells treated with or without FGFR1 inhibitor TKI258 (1 μM) for 4 hr were applied to western blot to detect acetylation of PDHA1 K202 (top) and PDP1 K321 (bottom).

(B) Endogenous PDP1 was immunoprecipitated from H1299 cells treated with or without FGFR1 inhibitor TKI258. Coimmunoprecipitated endogenous ACAT1 (top) and SIRT3 (bottom) were detected using western blot. HC, heavy chain.

(C and D) Endogenous ACAT1 (C) or SIRT3 (D) were immunoprecipitated from H1299 cells with stable knockdown of PDP1 (left) or PDHA1 (right), and coimmunoprecipitated endogenous PDHA1 or PDP1 were detected using western blot. SIRT3 was immunoprecipitated from TKI258-treated cells.

(legend continued on next page)
mitochondria (Figure 6K, left). Consistently, stimulation with EGF treatment resulted in increased Y381 phosphorylation of mitochondrial PDP1 in 3T3 cells, where mitochondria-localized EGFR was detected (Figure 6K, right). Thus, these results suggest that tyrosine kinase signaling commonly regulates the Y381 phosphorylation level of PDP1 to control mutually exclusive recruitment of ACAT1 and SIRT3 to PDC.

In addition, as shown in Figures 7A and 7B, respectively, both the GST-PDP1 Y381F mutant expressed by transient transfection in FGFR1-expressing H1299 cells and FLAG-PDP1 Y381F were pulled down from rescue cells and applied to western blot for detection of endogenous ACAT1 and SIRT3 bound to FLAG-PDP1 variants. Right: western blot was performed to detect the K202 acetylation level of FLAG-PDP1 as well as the K321 acetylation and S293 phosphorylation levels of endogenous PDHA1, which contributes to phosphorylation-dependent regulation of PDHA1 and subsequent PDC activity (active enzymes are marked by asterisks). The error bars represent mean values ± SD. See also Figure S7.

(Y381) Phosphorylation of PDP1 Is Important for Lysine Acetylation of PDP1 and PDHA1 and Contributes to the Enhanced Glycolysis in Cancer Cells

(A) GST-PDP1 WT and Y381F were expressed in H1299 cells by transient transfection. GST pull-down was performed, followed by western blot to detect endogenous ACAT1 and SIRT3 bound to GST-PDP1 as well as the K202 acetylation level of GST-PDP1 protein.

(B) Left: FLAG-PDP1 WT and Y381F were pulled down from rescue cells and applied to western blot for detection of endogenous ACAT1 and SIRT3 bound to FLAG-PDP1 variants. Right: western blot was performed to detect the K202 acetylation level of FLAG-PDP1 as well as the K321 acetylation and S293 phosphorylation levels of endogenous PDHA1, which contributes to phosphorylation-dependent regulation of PDHA1 and subsequent PDC activity (active enzymes are marked by asterisks). The error bars represent mean values ± SD. See also Figure S7.

(C) and (D) PDP1 Y381 rescue cells and control WT cells were tested for PDC flux rate (C) and cell proliferation rate under hypoxia (D).

(E) Proposed model shows that Y381 phosphorylation of PDP1 toggles recruitment of ACAT1 and PDP1 to regulate lysine acetylation status of PDHA1 and PDP1, which contributes to phosphorylation-dependent regulation of PDHA1 and subsequent PDC activity (active enzymes are marked by asterisks). The error bars represent mean values ± SD. See also Figure S7.
stably expressed in rescue H1299 cells (Figure S7A) have decreased K202 acetylation with reduced binding ability to ACAT1 but increased binding ability to SIRT3 compared to control PDP1 WT. Moreover, rescue expression of PDP1 Y381F also results in reduced K321 acetylation and S293 phosphorylation of PDHA1 (Figure 7B, right), along with an increased PDC flux rate and decreased cell proliferation rate under hypoxia (Figures 7C and 7D, respectively) as well as decreased lactate production and increased oxygen consumption rate (Figures S7B and S7C, respectively), similar to the phenotypes of K→R rescue cells of PDHA1 and PDP1 (Figure 2). These data together suggest that Y381 phosphorylation of PDP1 is sufficient and important to regulate lysine acetylation of PDP1 and PDHA1, as well as subsequent cancer cell metabolism and cell proliferation, by altering recruitment of ACAT1 and SIRT3 to PDC.

**DISCUSSION**

Our findings provide insight into the molecular mechanisms underlying PDC regulation, which complements the currently accepted model in which PDHA1 and subsequent PDC activity is regulated through cyclic serine phosphorylation and dephosphorylation. As proposed in Figure 7E, our results suggest that in normal, differentiated cells that predominantly rely on OXPHOS, PDC is physiologically activated, with the core of PDC consisting of active PDP1 and PDHA1, which have only basal lysine acetylation levels due to association of SIRT3. ACAT1 and PDK1 in such cells either are not part of PDC or their presence in PDC is relatively low. In contrast, in glycolytic, EGFR-stimulated cells where EGFR is activated and in cancer cells where tyrosine kinase signaling is commonly upregulated, Y381 phosphorylation of PDP1 occurs, leading to SIRT3 dissociation and ACAT1 recruitment. ACAT1 acetylates PDP1 at K202 and PDHA1 at K321, leading to dissociation of PDK1 from PDHA1 and recruitment of active PDK1 to PDHA1, respectively. The core of PDC thus consists of inactive PDHA1 with high levels of inhibitory S293 phosphorylation due to PDK1 recruited by PDHA1 with decreased enzyme activity (Jing et al., 2013). However, SIRT3 was suggested to deacetylate the K336 site of PDHA1. Interestingly, acetylated K321 of PDHA1 was detected in cells of many different cancer types, while PDHA1 K366 was detected as acetylated in human myeloid leukemia MV4-11 cells (http://www.phosphosite.org/proteinAction.do?id=1271&showAllSites=true). These findings may suggest that although lysine acetylation of PDHA1 represents a common regulatory mechanism in human cells, PDHA1 might be differentially acetylated in different cell types. In addition, Park et al. (2013) recently reported that SIRT5 regulates PDH activity through lysine desuccinylation. These findings, together with our own, suggest that different posttranslational modifications may coordinate to regulate PDH and consequent PDC activity.

Our findings also add to emerging evidence that has shown that lysine acetylation of metabolic enzymes is common and important to link cell signaling pathways to metabolic pathways in cancer cells (Choudhary et al., 2009; Kim et al., 2006b; Wang et al., 2010; Zhao et al., 2010). For example, Lv et al. reported that pyruvate kinase M2 isoform (PKM2) is acetylated at K305 and K433, leading to inhibition of PKM2 enzyme activity but enhanced nuclear accumulation and protein kinase activity of PKM2 in cancer cells (Lv et al., 2011, 2013). In addition, K5 acetylation promotes degradation of lactate dehydrogenase A (LDH-A), which is regulated by its upstream deacetylase SIRT2, and the K5 acetylation status of LDH-A inversely correlates with protein expression level of SIRT2 in tumor tissue samples from pancreatic cancer patients (Zhao et al., 2013). Increased lysine acetylation of ATP citrate lyase (ACLY), a key enzyme in lipid biosynthesis, was found in human lung cancers and stabilizes ACLY to promote fatty acid biosynthesis and consequent tumor growth (Lin et al., 2013).
ACAT1 is a key enzyme in ketogenesis by converting two acetyl-CoAs to acetocetyl-CoA and CoA (Balasse and Féry, 1989). ACAT1 is a mitochondrial protein acetyltransferase that is linked to cancer metabolism and tumor growth. In contrast, SIRT3 has previously been suggested to function as a tumor suppressor (Bell et al., 2011; Kim et al., 2010; Xiao et al., 2013) as well as a repressor of the Warburg effect through HIF-1α destabilization (Finley et al., 2011), which is consistent with our findings that deacetylation of PDHA1 and PDP1 by SIRT3 provides a disadvantage to cancer cell metabolism and cell proliferation. Future studies are warranted to explore how oncogenic signals coordinate the enzyme activity of ACAT1 and SIRT3 to regulate lysine acetylation levels of PDHA1 and PDP1 to promote glycolysis, which provides a metabolic advantage to cancer cell proliferation and tumor growth. Moreover, our finding that ACAT1 predominantly signals through PDP1 and PDHA1 to promote the Warburg effect and tumor growth suggests that the ACAT1-PDP1-PDHA1 axis represents a promising anticancer target. Functional attenuation of ACAT1 or activation of its downstream effectors PDP1 and PDHA1 could lead to attenuated cancer cell proliferation and tumor growth due to metabolic defects.

**EXPERIMENTAL PROCEDURES**

Screening for Upstream Acetyltransferases of PDP1

The identities of the lysine acetyltransferases in the human genome were provided by [http://www.phosphosite.org/psrSearchAction.do](http://www.phosphosite.org/psrSearchAction.do). We constructed a “targeted shRNA library” that targeted 50 out of 71 acetyltransferases genes, which are available in the shRNA library targeting the whole human genome (Open Biosystems). Each acetyltransferase gene was targeted by a shRNA pool that contains 2–5 different lentiviral-based shRNA constructs that target different regions of the target gene. A PDP1 phosphatase assay-based screening strategy was designed to identify the upstream acetyltransferase(s) of PDP1 using this shRNA library. In brief, H1299 lung cancer cells were infected with lentiviruses targeting each acetyltransferase. At 4 days after lentiviral infection, H1299 cells were treated with NAM+TSA for 16 hr. PDP1 assay was performed as described below using recombinant PDP1 incubated with 20 μg cell lysates.

Xenograft Studies and Primary Tissue Samples from Leukemia Patients and Healthy Donors

Approval of the use of mice and designed experiments was given by the Institutional Animal Care and Use Committee of Emory University. Approval of the use of human specimens was given by the Institutional Review Board of Emory University School of Medicine. All clinical samples were obtained with informed consent with approval by the Emory University Institutional Review Board. Clinical information for the patients was obtained from the pathologic files at Emory University Hospital under the guidelines of and with approval from the Institutional Review Board of Emory University School of Medicine and according to the Health Insurance Portability and Accountability Act. Detailed experimental procedures using mice and human primary tissue samples are described in the Supplemental Experimental Procedures.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online at [http://dx.doi.org/10.1016/j.molcel.2013.12.026](http://dx.doi.org/10.1016/j.molcel.2013.12.026).

**ACKNOWLEDGMENTS**

This work was supported in part by NIH grants CA140515 (J.C.), CA116804 (E.G.V.M.), the Pharmacological Sciences Training Grant T32 GM08602 (S.E.), DoD grant W81XWH-12-1-0217 (J.C.), the Samuel Waxman, Max Cure and V Foundations (E.G.V.M.), and the Hematology Tissue Bank of the Emory University School of Medicine and the Georgia Cancer Coalition (H.J.K.). J.X., M.T., T.-L.G., M. Aguiar, and S. Lonning are employees of Cell Signaling Technology, Inc. S.E. is an NIH predoctoral fellow and an ARCS Foundation Scholar. H.J.K., F.R.K., S. Kang, and J.C. are Georgia Cancer Coalition Distinguished Cancer Scholars. S. Kang is a Robbins Scholar. S. Kang and J.C. are American Cancer Society Basic Research Scholars. J.C. is a Scholar of the Leukemia and Lymphoma Society.

**REFERENCES**


**Molecular Cell**

**Lysine Acetylation Inhibits PDP1 and PDHA1**


